News

Hyasen Biotech Co., Ltd. as a professional pharmaceutical raw material supplier in Bio-pharma and In Vitro Diagnostics industry, is excited to announce its participation in the CACLP (China Association of Clinical Laboratory Practice) Ex...

2025 Medlab Middle East, held from February 3 to 6 at the Dubai World Trade Center. As the largest laboratory and IVD exhibition in the Middle East, the event served as a pivotal platform for global healthcare innovators to exchange idea...

Hyasen Biotech successfully participated in the PharmaTech & Ingredients 2024 exhibition, which was held at the Crocus International Exhibition Center in Moscow, Russia from November 19 to 22, 2024.

At the 56th International Medical Devices and Equipment Exhibition (Medica 2024) in Düsseldorf, Germany, which was held from November 11 to 14, 2024, Hyasen successfully participated in Medica and gained a lot with our excellent p...

Dear Partners,  We, Hyasen Biotech would like to express our sincere appreciation for your continued support in 2024. Your partnership has been vital to our shared success.   May Christmas bring light, love and peace to your ...

From June 19th to June 21st, Hyasen Biotech participated in the events of CPHI China held in Shanghai, which have concluded successfully!   During the events, our booth attracted significant attention of clients from different countries ...

Dear Friends We are happy to inform you that we are going to have the Dragon Boat Festival in China from 8th-10th June. Hyasen biotech is excited to join in the celebrations of this cherished Chinese tradition. this vibrant holiday is ...

On May 31, 2024, Moderna announced that it received FDA marketing approval for its RSV mRNA vaccine. mRNA-1345, the “first marketed non-COVID-19 mRNA vaccine” to be used for the prevention of RSV-associated lower respiratory tract diseas...